Deutsche Bank analyst Justin Bowers maintains $IQVIA Holdings (IQV.US)$ with a buy rating, and adjusts the target price from $270 to $265.
According to TipRanks data, the analyst has a success rate of 42.9% and a total average return of -0.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $IQVIA Holdings (IQV.US)$'s main analysts recently are as follows:
Iqvia's market is considered relatively stable, although the company is experiencing issues with bookings due to delays and drug failures rather than significant effects from pipeline rationalization.
The company has encountered a challenging industry operating environment. Commentary from the company indicates that pharma portfolio reprioritizations related to the IRA may be concluding, and it seems the company is likely to benefit from the pharmaceutical industry's consolidation of vendors.
Iqvia's recent financial performance surpassed consensus expectations in terms of total revenue, adjusted EBITDA, and adjusted EPS. However, the company has revised its 2024 outlook downward for all metrics. This revision is attributed to the impact of the Inflation Reduction Act and broader economic challenges. Additionally, the guidance for R&DS was lowered following the delay of two major trials and a cancellation.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
德意志銀行分析師Justin Bowers維持$艾昆緯 (IQV.US)$買入評級，並將目標價從270美元下調至265美元。
根據TipRanks數據顯示，該分析師近一年總勝率為42.9%，總平均回報率為-0.3%。
此外，綜合報道，$艾昆緯 (IQV.US)$近期主要分析師觀點如下：
Iqvia的市場被認爲相對穩定，儘管公司正在經歷由於預訂延遲和藥物失敗而導致的問題，而不是受到管線合理化的重大影響。
該公司遇到了具有挑戰性的行業經營環境。公司的評論表明，與IRA相關的藥品組合重新排序可能正在結束，看來該公司很可能從藥品行業的供應商整合中受益。
Iqvia最近的財務表現在總營業收入、調整後的EBITDA和調整後的每股收益方面超出共識預期。然而，公司已將2024年的所有指標展望下調。這一修訂歸因於通脹減少法案的影響和更廣泛的經濟挑戰。此外，由於兩項重大試驗推遲和一項取消，研發指導也有所降低。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
